An Exploratory Study to Investigate the Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid Using Open Flow Microperfusion After a Single Subcutaneous Administration of 300 mg in Healthy Subjects and Psoriatic Patients

Trial Profile

An Exploratory Study to Investigate the Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid Using Open Flow Microperfusion After a Single Subcutaneous Administration of 300 mg in Healthy Subjects and Psoriatic Patients

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Mar 2015

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Plaque psoriasis
  • Focus Pharmacokinetics
  • Acronyms OFM ISF
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 25 Mar 2014 Results presented at the 72nd Annual Meeting of the American Academy of Dermatology.
    • 25 Sep 2012 Planned end date changed from 1 Nov 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 06 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top